menu
    • menu
    [{"orgOrder":0,"company":"University of Reading","sponsor":"Naturex","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Reading \/ Naturex","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ Naturex"},{"orgOrder":0,"company":"University of Reading","sponsor":"Naturex","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of Reading","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Reading \/ Naturex","highestDevelopmentStatusID":"1","companyTruncated":"University of Reading \/ Naturex"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"VEGF","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AngioLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AngioLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AngioLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AngioLab \/ Undisclosed"},{"orgOrder":0,"company":"AngioLab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Melissa Officinalis","moa":"VEGF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"AngioLab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AngioLab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AngioLab \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Melissa Officinalis

    Menu

    Melissa Officinalis

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University of Reading

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Reading

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Naturex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enhancement of Calmness and Mood Following Acute Lemon Balm Supplementation During Cognitive Demand in Adults

                            Details : Lemon Balm is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Stress Disorders, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 27, 2023

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Naturex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Reading

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Reading

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Sleep

                            Study Phase : Undisclosed

                            Sponsor : Naturex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enhancement of Sleep Quality and Mood Following Supplementation With Lemon Balm in an Adult Population (Lemslp...

                            Details : Lemon Balm is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep Wake Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 16, 2022

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Sleep

                            Highest Development Status : Undisclosed

                            Sponsor : Naturex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AngioLab

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AngioLab

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

                            Details : ALS-L1023 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 13, 2020

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AngioLab

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AngioLab

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients Wi...

                            Details : ALS-L1023 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 31, 2018

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hanmi Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Hanmi Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

                            Details : ALS-L1023 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abdominal Obesity Metabolic Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 07, 2013

                            Lead Product(s) : Melissa Officinalis

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth